Lindsay Rosenwald | Dr Lindsay Rosenwald Biotechnology Investor

Immediately after going to Abington High School, Dr. Rosenwald began his health care training at PSU in 1973. He had a fascination with exactly how businesses worked and spent a fair amount of time learning about the financial features of their operation.

In pursuit of his lifelong wish, Lindsay Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before beginning his own private practice. After filling out his internship, he functioned as a medical professional in his private practice for 2.5 years. Though he liked practicing medicine Dr. Rosenwald sensed as if something was absent. He made the decision he needed to combine his 2 interests, business enterprise and medical science, and look for a career that would let him pursue those passions.

Lindsay Rosenwald eventually left his private practice in 1986 to go to Wall Street where he got on a position as a Physician / Analyst, an extremely exclusive placement with just a few people doing it at that time. In spite of the belief that doctors don’t make good investors, Dr Rosenwald excelled at this job. He worked here because he felt it was vital to focus on opportunities in the medicine and health sector. He received superb respect in his brand new position, and although he missed his old private practice, he knew this is where he truly belonged. He also worked for an exclusive investment company, DH Blair Co as the Controlling Director of Finance, but left after a few years to concentrate on a brand new enterprise.

With time, he has widened this company by establishing new companies and gaining control of other biotech firms. The business has financed more than two dozen businesses in the last three years. He is able to make these acquired companies successful because he focuses on both improving the corporate framework of the organization. All of these companies are separate entities, but interact to aid each other. The businesses that Rosenwald handles have licensed or obtained over a hundred experimental stage medicines.

Possibly one of Dr Rosenwald’s greatest accomplishments is that he set the record for the fastest development of a drug. In only thirty months, Arsenic Trioxide was developed and approved by the FDA for treating a deadly type of the leukemia disease. This medicine has been on the market worldwide for more than ten years and it has saved and extended 1000s of lives.

Rosenwald has been revolutionary with the firms he has created. One of his businesses sold to J&J for over One Billion Dollars despite the fact that they only had one medicine with phase 2 data. He is also the cause of bringing a stem cell business, a cancer vaccine organization, and a gene therapy company all to market. As Rosenwald as the leader, his companies have created many of the most valuable and groundbreaking drugs of the 21st century. To add to his achievements he created the first successful medicine to assist those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is he employs PHDs, MDs, MBAs, and other experts to function as his senior level professionals. These people provide plenty of experience in both the medical and business arenas that will help make his businesses more powerful and more diverse. They are driven to create new medicines as fast as possible. A few of these drugs have the potential to alter the way we view medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to medical and science instruction to help create the future of medicine.

Lots of people credit the success of the biotech industry on a whole to Dr. Lindsay Rosenwald. His visionary companies have altered many lives and made Dr. Rosenwald’s personal assets soar to the tune of $600 million.

In the past years, Dr. Lindsay A. Rosenwald had received a wide coverage in such public and trusted resources as MSN Money, The New York Times, Temple Times, and many others.

Michael Brush, a New York financial writer and a member of editorial staff at MSN Money, mentions Dr. Lindsay Rosenwald, among other venture capitalists. In his article, called “Company Focus. 4 picks from all-star insiders”, Brush writes about how the purchase of two biotech companies, Cell Therapeutics and Neose Technologies, increased profits of Lindsay Rosenwald’s companies to 100% to 280%. The average winnings generated over the six-month period following purchase in all the trades in these two stocks were 59% and 64%, respectively. Brush also writes about another biotech company, called Genta that interested Dr. Rosenwald at the time.

Lindsay Rosenwald is also featured in The New York Times. In the article, “BUSINESS PEOPLE; D.H. Blair Picks Doctor As Director of Finance”, Dr. Rosenwald’s path from the doctor’s office to the investment bank is described. After finishing college at Penn State, Lindsay Rosenwald was torn about what career to pursue. He was very good in finance and economics at Penn State, but he really wanted to be a doctor. This led him to the medical school at Temple University, where Rosenwald did consulting for health-care companies and managed money for physicians and his professors. For two years and a half had Dr. Rosenwald been involved into private practice, although he was lured to Wall Street, where he finally got to as a securities analyst. In a year, D.H. Blair assigned Rosenwald as Director of Finance in the premier firm on the Wall Street.

In an article at the online edition of Temple Times, Dr. Lindsay Rosenwald is mentioned among other prominent venture capitalists and employees in big corporations, who took off their medical degree for the world of business and finance. Lindsay Rosenwald is the most notable person in biotechnology financing sector. With offices on three continents, the company specializes in asset management, investment banking, and direct investing in the biotech and life-sciences industries.

Another coverage of the results of Dr. Lindsay Rosenwald’s activities can be found in the Reverse Merger book by David Feldman, one of the country’s leading experts on reverse mergers. In his blog Reverse Merger & SPAC Blog, you can find a short abstract from his book devoted to one of the biotechnology firms funded by Lindsay A. Rosenwald: As reported in the Reverse Merger Report, Cougar Biotechnology was sold in 2009 to Johnson & Johnson for $1 billion. The amount was really impressive! After Cougar was reverse merged with a Form 10 shell, its stock price had risen 145%, and this was one of the most successful reverse mergers in the history.